KRAS and neoplasm: The observation of both an activating KRAS and NRAS mutation in the same tumor is unlikely, suggesting that the discrepant KRAS variant might represent a false positive call (supported by the low VAF from pyrosequencing, and the different variants reported by pyrosequencing and the prior clinical real-time PCR method).